V1RC11 Inhibitors
V1RC11 inhibitors belong to a specialized class of chemical compounds that interact with biological systems by inhibiting the function of a specific protein or enzyme, typically denoted as V1RC11. The designation of this class of inhibitors usually follows a system where the name reflects the target of inhibition, which is crucial for understanding their mechanistic role within biochemical pathways. The proteins or enzymes that are inhibited by V1RC11 inhibitors are generally involved in a particular biological process or pathway, and the inhibition of these proteins can alter the normal functioning of that pathway.
The design and development of V1RC11 inhibitors are rooted in the principles of medicinal chemistry and biochemistry, where the structure-activity relationship (SAR) is a key factor. Inhibitors in this class are characterized by their ability to bind to the active site or another significant domain of the V1RC11 protein, blocking its interaction with natural substrates or cofactors. This binding is often highly specific, with the inhibitor molecule shaped in such a way that it fits into the target site on the protein, much like a key fits into a lock. The specificity is a result of meticulous chemical design, which ensures that the inhibitor interacts with the target protein with a high degree of affinity while minimizing interactions with other proteins. The chemical structure of V1RC11 inhibitors typically features a combination of moieties that are essential for binding, including hydrogen bond donors or acceptors, hydrophobic regions, and possibly ionic groups that interact with corresponding features on the protein surface. These interactions are critical for the inhibitor's efficacy, and slight modifications to the chemical structure can dramatically affect the binding affinity and specificity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinases (PI3K) inhibitor that blocks the PI3K/Akt signaling pathway. As V1RC11 is downstream of this pathway, its activation can be negatively impacted by LY294002 since PI3K inhibition would lead to reduced Akt activity, thereby potentially reducing the phosphorylation and activity of V1RC11 if it is dependent on this pathway for its activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of mitogen-activated protein kinase kinase (MEK), which in turn inhibits the extracellular signal-regulated kinase (ERK) pathway. Inhibition of MEK by PD98059 may impede the phosphorylation events necessary for V1RC11 function, assuming that V1RC11 requires ERK-mediated signaling for its activation or stabilization. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A selective inhibitor of p38 MAP kinase. Since p38 MAP kinase is involved in stress responses and inflammation, inhibition by SB203580 could result in altered cellular responses that indirectly affect the activity of V1RC11, particularly if V1RC11 is implicated in such cellular processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another potent PI3K inhibitor similar to LY294002, wortmannin leads to inhibition of the AKT signaling pathway. By preventing PI3K activity, wortmannin can indirectly cause reduced V1RC11 activity if V1RC11 is functionally linked to the PI3K/AKT pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An inhibitor of the mammalian target of rapamycin (mTOR), which is a key regulator of cell growth and proliferation. By inhibiting mTOR, rapamycin can decrease protein synthesis and cell survival signaling, which can indirectly affect V1RC11 activity if it is regulated by these pathways. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
A selective inhibitor of Src family kinases. Src kinases can phosphorylate a variety of proteins involved in signaling pathways, and if V1RC11 activity is regulated by Src kinases, then PP2 can serve to reduce its activity through inhibition of these kinases. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of both MEK1 and MEK2, similar to PD98059. U0126 prevents the activation of ERK1/2, potentially affecting proteins downstream of this pathway. If V1RC11 relies on MEK/ERK signaling for its activation, then U0126 would lead to decreased V1RC11 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which can influence apoptotic and survival pathways. Inhibition of JNK by SP600125 could interfere with V1RC11 activity if V1RC11 is associated with pathways that involve JNK signaling. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
An inhibitor of NF-κB activation by blocking the phosphorylation of IκBα. NF-κB is a transcription factor involved in the expression of various genes. BAY 11-7082 could decrease V1RC11 activity if V1RC11 is regulated by genes under the control of NF-κB. | ||||||
LFM-A13 | 62004-35-7 | sc-203623 sc-203623A | 10 mg 50 mg | $119.00 $670.00 | ||
A selective inhibitor of Bruton's tyrosine kinase (Btk), which is important for B cell development and function. If V1RC11 plays a role in B cell receptor signaling, the inhibition of Btk by LFM-A13 could lead to a decrease in V1RC11 activity. | ||||||